CombiMatrix announced that the DoD has awarded a one-year, $2.2 mln contract to CombiMatrix for further development of its microarray technologies for a multipathogen- and chemical-detection system.
Imagine a diabetic patient from NewYork being put on a drug regimen distinct from a patient London. Personalized medicine allows tratement to decided on the genetic make up of the individual. Genetically europeans and asians and others have different ways of responding to same treatment genetically
FortunatelyIf Indian researchers have their way, such customised medication based on genetic differences could be a possibility for a range of illnesses.
A consortium of Indian scientists recently completed a genetic database for India, home to one of the world’s most ethnically diverse populations that will allow researchers to understand the genetic predisposition of ethnic groups to diseases. Icelanders are considered for Human genome project because of very less number such diversity
The genetic map will enable global and Indian pharma companies to enhance research on predictive medicine and targeted drugs. Research firm TCG Life Sciences is about to become the first private player to use the database.
The consortium collected data on the genetic codes of over a 1,000 genes from among 15,000 individuals belonging to Indian sub-populations
Another user of the data is the clinical diabetics’ consortium, which aims to identify if there are specific genetic reasons for a particular ethnic group to be predisposed to the disease. It is already known that some cultures are pre disposed to certain diseases so Indian are more prone to heart attack and diabetes and such
The Indian Genome Variation Consortium, a public-private partnership that networks six Council of Indian Scientific and Industrial Research labs and some private software firms, undertook the genetic variation mapping.
Filed under: clinical diagnostics, DNA database, DNA diagnostics, DNA therapeutics, gene expression, gene therapy, genetic medicine, genetics, genotyping, microarray blog, personalized medicine, Pharmacogenomics | 7 Comments »
The complete list is published at forbes website
- Breast Cancer
- Adult-Onset Diabetes
- Drug Metabolism
- Crohn’s Disease
- Prostate Cancer
- Duchenne Muscular Dystrophy
- Rett Syndrome
- Macular Degeneration
- Alzheimer’s Disease
- Heart Attack
Filed under: clinical diagnostics, diagnostic microarray, DNA diagnostics, DNA medicine, DNA therapeutics, gene expression, genetics, Genomics, microarray, microarray for clinical diagnostics, personalized medicine, Pharmacogenomics | 1 Comment »
During 10th Annual Meeting of the American Society of Gene Therapy (ASGT) in Seattle a new methid for Regulating Expression of therapeutic Genes was introduced.
For many applications, gene transfer is being employed to engineer cells for therapeutic applications, chek the following links for article 1 IFR , 2 (Nature), 3 (NIH) , that require precise regulation in order to ensure gene expression in the correct tissue and prevent it in unwanted cell types,
Now, a team of scientists led by Dr. Luigi Naldini at the San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET) in Milan have developed a new design that enable delivered genes to become highly responsive to a cell’s identity with the helps of gene regulation mediated by small RNA molecules, known as microRNA. This is particularly relevant for the emerging field of stem cell gene therapy, in which genes are delivered into a cell that can give rise to many distinct cell types.
MicroRNAs downregulate the expression of specific genes in cells where the gene is not needed, and thereby have an important influence over the identity of the cell.
Addition of microRNA binding sites into their gene delivery vectors results in gene regulation dictated by the cell’s own microRNA. Simply put, they could engineer their gene to be turned off in cells where the microRNA is present.
Dr. Naldini’s group has already begun to successfully exploit microRNA regulation for achieving stable long-term correction of hemophilia in the mouse model and for improving the safety of hematopoietic stem cell gene therapy.
Filed under: bioinformatics blog, DNA, DNA medicine, DNA network, DNA news, DNA therapeutics, gene expression, gene therapy, genetic medicine, genetics, personalized medicine, Pharmacogenomics, transgenomics | 1 Comment »
AGI Dermatics a biotechnology company specializing in DNA skin repair and photobiology claims to be working on a DNA damage-control product thus far is called Dimericine Currently in stage-three clinical trials.
Dimericine, the company claims to contain, a customized enzyme that can recognize DNA damage caused by ultraviolet light and speed up repair
“We call it a morning-after lotion. It can be used after sun exposure but before damage has arrived. says the president of the company